Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Status:
Active, not recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying the safety and tolerability of an investigational combination
of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant
prostate cancer.
The interventions involved in this study are:
- Radium-223
- Pembrolizumab